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Background: Despite comparable screening rates for precancerous lesions, higher incidence and mortality related
to cervical cancer in minority women persists. Recent evidence suggests that minority women with precancerous
cervical lesions harbor a wider range of human papillomavirus (HPV) genotypes, many of these distinct from
HPV16/18, those most commonly found in Caucasian women. The goal of the analysis was to determine if
inflammatory cytokines and chemokines varied by HPV 16/18 versus other genotypes in cervical cancer tissues from
Tanzanian women.
Methods: HPV genotypes and concentrations of chemokines and cytokines were measured from homogenized
fresh tumor tissue of thirty-one women with invasive cervical cancer (ICC). Risk factors for cervical cancer including
age, parity, hormonal contraceptive use and cigarette smoking were obtained by questionnaire. Generalized linear
models were used to evaluate differences between chemokines/cytokine levels in women infected with HPV16/18
and those infected with other HPV genotypes.
Results: After adjusting for age, parity and hormonal contraceptives, IL-17 was found significantly more frequently
in invasive cervical cancer samples of women infected with HPV16/18 compared to women infected with other
HPV genotypes (p = 0.033). In contrast, higher levels for granular macrophage colony-stimulating factor (p = 0.004),
IL-10 (p = 0.037), and IL-15 (p = 0.041) were found in ICC tissues of women infected with genotypes other than
HPV16/18 when compared to those of women infected with HPV16/18.
Conclusions: While the small sample size limits inference, our data suggest that infection with different HPV
genotypes is associated with distinct pro-inflammatory cytokine expression profiles; whether this explains some of
the racial differences observed in cervical cancer is still unclear. Future studies are needed to confirm these findings.
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Despite major reductions in incidence and mortality
over the last decade, an estimated 12,340 cases of in-
vasive cervical cancer (ICC) continue to be diagnosed
in the United States annually, with the highest inci-
dences in Hispanic and African American women
when compared to European American women [1].
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accounted for most of the overall decline in incidence
and mortality, but are comparable among African
Americans, Hispanics and European Americans, and
thus fail to explain the racial/ethnic discrepancies in ICC
incidence and mortality [2-4].
Reasons for continued racial/ethnic disparities in ICC
incidence and mortality are still unclear, although pub-
lished data in the last few years suggest that among
women with precancerous lesions, African Americans
may harbor human papillomavirus (HPV) genotypes dis-
tinct from those found in European American womenhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sions and do not include invasive cancer cases, and in gen-
eral, analyses are conducted in cells obtained from cervical
scrapes. We previously found among African women that
HPV 31, 35, and 45 in addition to HPV 16 and 18, were
the genotypes most frequently found in ICC cases [8].
While HPV 16 was found in 73% of the tissue samples in
those ICC cases with multiple infections, and HPV 35 and
45 were found in 33%, and HPV 18 in 21% of ICC tissue
samples, it is possible that co-infection with high-risk
(HR)-HPV 35 and 45 may have also influenced progres-
sion to ICC in these women. Nonetheless, these findings
raise the possibility that different immune responses to
persistent infection with distinct HR-HPV genotypes may
explain some of the ICC racial/ethnic disparities observed
worldwide [9].
It is known that HR-HPV initiates local Th2 inflamma-
tion at an early stage, involving antibody forming cells,
which fosters an immunosuppressive microenvironment
that aids tumor progression [10]. Indeed, Paradkar et al.
[11], have proposed using cytokine level measurements as
biomarkers for risk-stratification of patients with precan-
cerous lesions. Increased IL-17 expression is associated
with cervical cancer cell growth along with IL-6 levels in
tumor tissues; IL-17 may act through IL-6 [11]. In addition,
increased levels of IL-10, one of the best-studied Th2 type
cytokines which has a general immunosuppressive function
[12], has been associated with risk of high-grade cervical
lesions [13-15]. Furthermore, Scott et. al. [16] reported that
significantly increased levels of MIP-1a, TNF, IL-12 and IL-
10 cytokines were associated with a reduced likelihood of
any HPV clearance (including low and high-risk types)
among women with incident HPV infections, but without
cervical intraepithelial neoplasia (CIN).
In this analysis we examined a wide spectrum of cy-
tokines and chemokines present in ICC tissues from
Tanzanian patients to determine if cytokine levels dif-




Study procedures were approved by Research Ethics
Boards at KCMC and Duke University School of Medi-
cine Institutional Review Board, and all study partici-
pants signed an informed consent explaining the nature
of the study. The patients included in the present analyses
were part of a case–control study aimed at identifying epi-
genetic marks (DNA methylation and gene expression
profiles) associated with progression from CIN-1 to inva-
sive cancer. Detailed methods of patient identification and
enrollment have been described elsewhere [8,17]. Briefly,
between November 2008 and March 2009, eligible study
participants were identified from the appointment booksof the Reproductive Health Clinic (RHC) at Kilimanjaro
Christian Medical Centre (KCMC), a Cervical Cancer pre-
vention clinic funded by the World Health Organization
(http://www.afro.who.int/en/tanzania/who-country-office-
tanzania.html). KCMC is a tertiary care facility that serves
a catchment area of ~10 million individuals. Eligible par-
ticipants were 18 years or older and had no history of an
abnormal Pap test. ICC patients comprised new cases with
no history of cervical abnormalities who were also 18 years
or older and were referred for colposcopic directed evalu-
ations. A trained nurse interviewer enrolled a total of 249
women; all but 2 approached agreed to participate (99%
response rate). Of these, 12 patients were excluded due to
missing or inadequate Pap smear, refusal of an HIV-1 anti-
body test, and diagnosis of an unrelated co-morbid condi-
tion. The final number of participants, n = 215 (86%),
included participants who completed questionnaire, and
the availability of CIN status, and HPV genotype data.
Among the n = 215 participants, n = 40 were histologically
confirmed ICC cases and n = 37 were further genotyped
for any HPV infection. Of these n = 37, we excluded 4
cases that did not harbor HPV infection and 2 cases with
insufficient tissue available to homogenize. Thus, thirty-
one women had adequate tissue to successfully measure
cytokine/chemokine profiles from homogenized tissue.
Data collection
A trained nurse-interviewer obtained informed consent
from all participants, and administered a standardized
40-minute questionnaire in person. The questionnaire
collected information on socio-demographic characteris-
tics (e.g., age, marital status), type of marriage (polygamy
vs. monogamy), tribe, educational attainment, cigarette
smoking, alcohol intake, reproductive history (e.g., me-
narche, parity and gravidity), sexual history (e.g., lifetime
number of sexual partners, age at first intercourse), and
medication and supplement use.
Specimen collection and handling
Biopsies of lesions were obtained during colposcopy for
all cancers for histological evaluation as part of routine
patient care, and ICC was diagnosed by Hematoxilin and
Eosin staining. A portion of tumor samples was aliquoted
and immediately placed on dry ice, for research purposes.
Following specimen collection, routine cervical visual in-
spection was also performed and treatment conducted ac-
cording to standard clinical protocol.
Pathologic diagnosis of CIN and Carcinoma
Papanicolaou smears and biopsy specimens were proc-
essed and read by the staff pathologist at KCMC using
standard conventions according to ASCCP guidelines as
appropriate (http://www.asccp.org/). Once a month, med-
ical charts were reviewed by KCMC staff pathologist for
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using the Bethesda classification system [18]. Based on
pathology and medical records findings, results were then
coded as “no evidence of cytological abnormality”, “mild
dysplasia” including LSIL and CIN1, “moderate dysplasia”
including HSIL and CIN2-3, or “cancer” which included
squamous cell carcinoma and two adeno-squamous car-
cinomas of the uterine cervix. None of the specimens
were read as “atypical cells of uncertain significance
(ASCUS)”. These results were available as part of clinic
records, and pathologists entered them into the data-
base. These clinical results were then compiled and
transferred according to protocol.
HPV genotyping
ThinPrep® specimens and homogenized aliquoted biop-
sies collected during the same visit were shipped to the
University of Hawaii Cancer Center. Following DNA ex-
traction, PGMY09/PGMY11 primers [19,20] were used
in PCR to target a 450-bp region of the HPV L1 gen-
ome. Amplification of the human β-globin gene was in-
cluded as an internal control for sample sufficiency. All
specimens were suitable for viral DNA analysis. HPV-
positive specimens were subsequently genotyped by using
the HPV Linear Array® (Roche Molecular Systems Inc.,
Branchburg, NJ, USA).
Cytokine measurements
Thirty-one tumor tissues were homogenized in Tissue
Extraction Reagent I (Life Technologies/Invitrogen, Grand
Island, NY) using a Qiagen TissueRuptor (Qiagen,
Valencia, CA), centrifuged to pellet debris, and the super-
natant removed and frozen at −80°C. Frozen samples were
shipped to the ProteoGenomics Facility at the Medical
University of South Carolina on dry ice, for analysis using
the Human Cytokine Magnetic 30-Plex panel (IL-15, IL-4,
IL-2, IL-1RA, IL-1B, IL-5, IL-6, IL-7, IL-8, EGF, IL-13, IL-
12, IL-10, IL-2R, IL-17, HGF-35, TNF-alpha, IFN-alpha,
IFN-gamma, CCP1/MCp1, MIP-1B, MIPI-1A, VEGF,
FGF-B, FGF-12, MIG-63, GMCSF27, IP-10, G-CSF, and
RANTES, Life Technologies) according to manufac-
turer’s instructions, which included room temperature
incubation, with agitation, of samples with antibody
beads in 96-well plates; room temperature incubation with
biotinylated detector antibodies; and room temperature
incubation with streptavidin-R-pycoerythrin. Between in-
cubation steps were decanting and washing steps, using a
magnetic plate separator. Finished plates were scanned
using a Luminex Multiplex Bead Array system (Bio-Plex
200, Bio-Rad, Hercules, CA). Standards provided with the
Cytokine panel were serially diluted to 7 concentrations
according to manufacturer’s protocols, and included in
the 96-well plate with tumor samples for processing.
Specimens were run in duplicate and the ranges ofdetected values and coefficients of variation (CV) for
IL-17, GMCSF27, IL-10 and IL-15 were 1.47-198.1 pg/ml,
%CV 0–110.96%; 1.35-215.12 pg/ml %CV 0.35-57.47;
2.53-327.55 pg/ml, %CV 0–27.08%; and 50.94-796.76pmg/
ml, %CV 0.23-26.44%, respectively. Additional file 1: Table
S1 shows ranges of detection values for all 30 cytokines/
chemokines analyzed, and the number of samples for
which cytokines/chemokines were under the detection
limits. For IL-10 and GMCSF all samples were within de-
tection limits. For IL-17, there were 2 samples under the
detection limits, which were excluded from analysis. And
for IL-15, 10 samples were under detection limits and also
excluded from analysis (Additional file 1: Table S1).
Statistical analysis
The goal of the analysis was to determine if cytokines
and chemokines examined varied significantly based on
infection with HPV 16 or 18 or other genotypes. All
women infected with HPV 16 or 18, regardless of infec-
tion with other HPV genotypes were designated to have
HPV 16/18. All women with no detectable HPV16 or 18
were designated ‘other’. One woman with no detectable
HPV was excluded from analysis. T-tests were used to
examine if there were differences in cytokine/chemokine
abundance between women infected with HPV16/18 and
those infected other HPV genotypes. The natural loga-
rithm of cytokines/chemokines values was used in all the
analyses. Of the 30 cytokines and chemokines examined,
those significantly different (p < 0.05) were further evalu-
ated in generalized linear regression models (GLM) to ad-
just for potential influence of hormonal contraceptives
use, parity and age; among the 31 cancer cases analyzed,
2 reported smoking and all were multiparous. Regarding
lifetime sexual partners, as previously described [8],
cancer cases reported either 1 or 2 sexual partners. Only
3 women reported 3 lifetime sexual partners and none
reported more than 3 lifetime sexual partners. Exclud-
ing the three cases with 3 lifetime sexual partners and
the 2 smokers from the statistical models did not alter
the findings. Four women were also infected with HIV-
1; after excluding them from analysis, results remained
unchanged. All p-values reported are two-sided. Statistical
analyses were conducted using SAS 9.2 (SAS Institute,
Cary, NC).
Results
Table 1 summarizes the distributions of established risk
factors for ICC and infection with human papillomavirus,
dichotomized by HPV genotype 16 or 18 vs. others. We
found that among the 31 cases of ICC, women with geno-
types HPV 16/18 were younger (mean age = 51.86 years,
sd = 11.34) compared to women who did not harbor HPV
16/18 (mean age = 60.11 years, sd = 12.17) (p = 0.041). The
mean number of HPV genotypes among the group with







Age* 60.11 (12.17) 51.86 (11.34) 0.041
(44–82) (29–75)
Smoking 0.350
Yes 0 2 (9.1)
No 9 (100) 20 (90.91)
Number of HPV types* 0.992
1.44 (1.74) 3.05 (.32)
(0–5) (1–6)
Oral Contraceptive Use 0.397
Yes 3 (33.3) 11 (50)
No 6 (66.7) 11 (50)
ICC cases with and without HPV 16/18 infection. Of 31 ICC cases, 22 had
HPV 16/18, which were statistically younger than ICC cases with no HPV16/18
infection (p=0.041). No differences were observed in number of HPV types and
oral contraceptive use between ICC cases. Only 2 women reported smoking.
*For age and number of HPV types, mean, SD and range are reported.
For all other variables, frequency and percentages are reported.
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of HPV genotypes among women with no HPV 16 and/or
18 was 1.44 (sd = 1.74) (p = 0.992). There were no differ-
ences in oral contraceptive use between groups (p = 0.397).
All women were multiparous and only 2 (among those
infected with HPV 16 and/or 18) of the 31 reported
smoking cigarettes.
The prevalence of HPV16 or 18 was comparable in
the overall sample of 40 representing all ICC cases previ-
ously reported [8], and in this sub-sample of 31 in which
cytokines were successfully measured (73%, 95% CI = 65%
to 81%). We found that in this population of African
women, and as previously described [8], the 31 cancer
samples had multiple infections with high-risk types HPV
16 (73%), HPV 18 (21%), HPV 35 (33%), HPV 45 (30%),
HPV 31 (18%), HPV 52 (15%), HPV 33 (9%), HPV 58 (6%),
and HPV 68 (3%) [8]. HPV16 and 18 were present in 22
ICC cases out of 31.
Among a panel of 30 cytokines and chemokines in-
cluding IL-15, IL-4, IL-2, IL-1RA, IL-1B, IL-5, IL-6, IL-7,
IL-8, EGF, IL-13, IL-12, IL-10, IL-2R, IL-17, HGF-35,
TNF-alpha, IFN-alpha, IFN-gamma, CCP1/MCp1, MIP-
1B, MIPI-1A, VEGF, FGF-B, FGF-12, MIG-63, GMCSF27,
IP-10, G-CSF, and RANTES, measured in homogenized
cervical cancer tissues, we detected a trend for differences
between cytokines/chemokines and HPV16/18 status; in
general, pro-inflammatory cytokines/chemokines were
higher in women infected with HPV 16/18 compared to
those infected with HPV genotypes other than HPV16/18.
However only four cytokines varied significantly between
ICC harboring HPV 16 or 18 vs. ICC harboring non HPV
16 or 18 (Figure 1).We found that women infected with HPVs other than
16 or 18 had lower concentrations of IL-17 when com-
pared to those who carried HPV 16 and/or 18 (p = 0.0006)
after adjusting for oral contraceptives and parity; these
findings were significant even after applying the stringent
Bonferroni correction (0.05/30 = 0.0017). However, further
adjusting for age somewhat weakened these associations
although they remained statistically significant (p = 0.033)
(Figure 1). Cancer tissue from women not infected with
HPV 16 or 18 had higher concentrations of GMCSF
(p = 0.004), IL10 (p = 0.037), and IL15 (p = 0.041), when
compared to those of women infected with HPV16/18
(Figure 1), after adjusting for age, parity and hormonal
contraception. IL-6 was also higher in cancer samples
with HPV other than 16 and 18, however the differences
were not statistically significant (data not shown). Re-
peating these analyses excluding the two smokers and
the 4 cases infected with HIV-1 did not alter these find-
ings. No other chemokine/cytokine significantly differed
between cancer cases that harbored HPV16/18 and those
that harbored other HPV genotypes.
Discussion
Although 70% of invasive cervical cancer cases are
thought to be caused by HPV 16 and 18, recent data sug-
gest that even in severe cervical intraepithelial neoplasia,
women of African descent are two times less likely to be
infected with HPV 16 and 18 [5-7]. This observation sug-
gests that invasive cervical cancer may be driven by a
more diverse set of HPV genotypes in this population,
which has important implications in screening for precan-
cerous lesions [7]. Reasons for these differences are still
unclear, although previous findings have been complicated
by the use of cervical scrapes, which include cancer cells
and normal cells distal to the tumor. Previous studies
have also been difficult to assess because of a higher
genetic admixture found in African Americans [21]. But
most importantly, there are few studies that included
cervical tumor tissue.
In these analyses, we tested the hypothesis that im-
mune response may be different in individuals infected
with HPV other than 16 and 18, by comparing the levels
of cytokines and chemokines in cervical tissues of women
infected with HPV 16/18 to those infected with other
HPV genotypes in an African population. Our key finding
was that there were significantly lower levels of IL-17 and
higher levels of IL-10, IL-15 and GMCSF in women who
carried HPV genotypes other than HPV16 and 18. These
data are consistent with the hypothesis that different HPV
genotypes may elicit a different immune response.
These data extend previous work by including a larger
number of cytokines. These data also support the hypoth-
esis that infection with HPV genotypes other than 16 and
18 is associated with an immune response different from
Figure 1 Cytokine concentrations in ICC samples infected with HPV 16/18 vs. ICC samples without HPV 16/18. P-values from generalized
linear models, after adjusting for age, parity and hormonal contraceptive use.
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infected with non-HPV16/18 genotypes (predominantly of
African descent) may be more likely to progress from
HPV infection to ICC.
Our finding that pro-inflammatory IL-17 levels in cer-
vical tissues were significantly higher in women infected
with HPV 16 and/or 18 is in agreement with other stud-
ies that reported an association between increased IL-17
levels and cervical cancer cell growth both in human
and in animal studies [22,23]. Furthermore, the evidence
that IL-17 expression was lower in ICC tissue that did
not harbor HPV16 or 18 suggests that other cytokines,
which may include GMCSF, IL-10 and IL-15, may trigger
an immunosuppressive response that is permissive for de-
velopment of ICC when the cervical tissue is infected with
other non-HPV16 or 18 HR-HPV genotypes. The sample
size was too limited for us to model this possibility.
Previous studies have reported on the dual biological
function of IL-10 as an anti-inflammatory (potentially
cancer-promoting) and anti-angiogenic (potentially cancer-
inhibiting) agent, which reflects the conflicting data in cer-
vical cancer [24]. Increased expression of IL-10 was shown
to be associated with decreased risk of CIN2/3 lesions,
when controlled for potential confounders [25]. However,
Syrjänen et al., 2009 [26] found that IL-10 up-regulation in
baseline biopsies was most consistently associated withhigh-grade CIN, but the expression profile of this cytokine
was unrelated to HR-HPV genotypes or viral load, and was
not a predictor of viral outcome and disease progression in
a longitudinal setting. After accounting for high-risk-HPV,
age, and use of oral contraceptive, they found IL-10 was an
independent covariate of CIN2/3, suggesting that this im-
munosuppressive cytokine might play an important role in
creating a milieu that favors progressive cervical disease
[26]. None of these studies however analyzed the data by
HPV 16 or 18 vs. other HR-HPV genotypes, which could
add another dimension to the immune response elicited by
IL-10 towards progression from CIN2/3 to ICC.
Our study has several limitations including the small
number of ICC cases examined and thus we cannot draw
definitive conclusions. Even though we had data on HIV-1
infection, data on Th2/Th1 response, haematological evi-
dence of autoimmune disorders and other immunological
records were not available, thus while unlikely, we cannot
rule out that some of the differences found could be due
in part to immune disorders, as well as the fact that
women infected with HPV 16/18 were on average infected
with a higher number of HPV genotypes than the group
without HPV 16/18. A key question that remains to be an-
swered, if interventions aimed at reducing disparities are
to be effective, is whether or not race/ethnicity differences
observed are the consequence of a higher propensity for
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ethnic groups. If so, this may suggest differences in im-
munological response to HPV or co-infections. However,
our cohort included only African women whose cytokine
profile may not be comparable to that in ICC samples of
white women. Although, we had 31 ICC cases with con-
firmed HPV infection obtained directly from the lesion.
Conclusions
These findings indicate that distinct HR-HPV genotypes
may induce different immune responses that facilitate
progression from CIN to ICC, which may vary by race/
ethnicity. Such inflammatory markers could be useful in
risk stratification to discriminate women likely to progress
among those with abnormal cytological findings and HPV
infection. Future studies in multiethnic cohorts are needed
to confirm this hypothesis.
Additional file
Additional file 1: Table S1. Detection ranges of the 30 cytokines/
chemokines studied. In column three the number of samples with
cytokines/chemokines under the detection limit, are shown. Those
samples were excluded from analysis (*). Seven RANTES samples with
detection ranges over the limit were also excluded from analysis.
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